

Table S1. Immune and/or Host Defense Functions of single nucleotide polymorphisms associated with depression based on meta-analyses of genome-wide association (GWAS) studies

Liu et al. Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. <i>Mol Psychiatry</i> 2011; 16: 2-6 ^(a)		
Gene ID	Gene Name	Immune Function of Gene
<i>CACNA1C</i>	calcium channel, voltage-dependent, L type, alpha 1C subunit	See article text for a discussion of immune and host defense functions of <i>CACNA1C</i>
McMahon et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. <i>Nat Genetics</i> 2010; 4: 128-31 ^(a)		
Gene ID	Gene Name	Immune Function of Gene
<i>PBRM1</i>	polybromo 1 <u>aka</u> BRG1-associated factor 180 (BAF180)	PBRM1 codes for a protein component (BRG1-associated factor 180 [BAF 180]) of the SWI/SNF chromatin remodeling complex, which is crucial for activation and proliferation of T cells in response to antigen stimulation, ¹ and which regulates induction and temporal sequencing of proinflammatory cytokines in response to an immune challenge, ² as well as antigen receptor assembly (i.e. VDJ recombination) in B cell precursors; ³ following bacterial TLR stimulation, the BRG1/BRM subunits of the SWI/SNF complex are consistently required for the activation of secondary response genes and primary response genes induced with delayed kinetics within macrophages; ⁴ BRG1 and other BAF elements within the SWI/SNF complex has been identified as activators of transcription within the nuclear interactome for the HIV-1 virulence factor “Trans-Activator of Transcription” (Tat), ⁵⁻⁷ and the SWI/SNF complex more generally regulates retroviral gene integration into, and expression in, infected host cells, ⁸⁻¹¹ and contributes to viral replication; ¹² PBRM1 (BAF 180) is required for expression of the IFITM1 gene in response to interferon signaling, ¹³ and IFITM1 has been shown to restrict entry of a range of viruses, including HIV and SARS, into host cells, ^{14,15}

		consistent with fact that BAF complex within SWI/SNF is essential for IFN-target-gene dependent cellular antiviral activities; ¹⁶ BRG1 is essential for IFN-gamma induction of CIITA, the master regulator of major histocompatibility complex (MHC) class II expression, ¹⁷ and a switch from hBrm to BRG1 regulation of expression is an indicator of genes that are responsive to IFN-gamma signaling; ¹⁸ BRG1 contributes to MHC I immunity by upregulating enhancer A; ¹⁹ knock-down of BRG-1 activity blocks human papillomavirus E-2 driven transcriptional activation and DNA replication; ²⁰ mice that constitutively express the SWI/SNF complex are highly susceptible to experimentally induced autoimmune encephalomyelitis; ¹
<i>GNL3</i>	guanine nucleotide binding protein-like 3	<i>GNL3</i> codes for a GTPase nucleostemin that is involved in stem cell proliferation and that upregulates the transcription factor <i>CDX2</i> , ²¹ which is a homeodomain transcription factor specific to the intestinal epithelium crucial for pathogenic <i>E. coli</i> to induce the di/tripeptide transporter <i>PepT1</i> in gut and also to activate <i>NFκB</i> and <i>MAPK</i> leading to production of <i>IL-8</i> . ²² The chemokine <i>CCL25</i> which plays an important role in recruiting lymphocytes to the intestinal epithelium is enhanced by <i>CDX2</i> , which regulates <i>CCL25</i> transcription. ²³ <i>CCL25</i> , in turn, is believed to play a role in the development of T cells, ²⁴ and is chemotactic for thymocytes, macrophages and dendritic cells. ^{25,26}
<p>Shyn et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. <i>Mol Psychiatry</i> 2011; 16: 202-15^(b)</p>		
Gene ID	Gene Name	Immune Function of Gene
<i>ATP6V1B2</i>	ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2	<i>ATP6V1B2</i> is a component of vacuolar ATPase (V-ATPase) that is involved in cytoskeletal functioning necessary for T cell movement and ability to form functional immunological synapses with antigen presenting cells; ²⁷ V-ATPase is important for host defense against <i>M. tuberculosis</i> by contributing to phagosomal maturation/acidification; ²⁸ via secretion of <i>SidK</i> <i>L. pneumophila</i> (cause of Legionnaires' disease) inhibits V-ATPase allowing for vacuolar survival and enhanced virulence; ²⁹ V-ATPase contributes to early intracellular survival strategy of <i>F. Tularensis</i> ; ³⁰ V-ATPase is a target for <i>P. aeruginosa</i> produced pyocyanin, which kills competing microbes and mammalian cells during pseudomonal infection; ³¹ by contributing to endosomal acidification V-ATPases promote influenza A virus infection, ³² conversely V-ATPase inhibition has been shown to be protective against highly virulent

		influenza strains; ³³ V-ATPase inhibition inhibits rhinovirus infection of airway epithelial cells via blocking viral RNA entry into endosomes and by reducing ICAM-1 expression in epithelial cells. ³⁴ during pregnancy and in tumorigenesis, α 2NTD, which is cleaved from the α 2 isoform of V-ATPase upregulates pro- and anti-inflammatory mediators including IL-1b and IL-10; ³⁵⁻³⁸ V-ATPase promotes fetal implantation and survival by modulating cytokine network at implantation site and attenuating maternal immune response against fetal trophoblast cells; ³⁸
<i>SP4</i>	Specificity protein 4 transcription factor	SP4 activates the HIV-1 LTR promoter, ³⁹ possibly enhancing HIV-1 Tat-mediated transactivation of the viral promoter. Consistent with these effects an intergenic SNP in <i>SP4</i> (rs6951646) may confer vulnerability for mother-to-child transmission of HIV; ⁴⁰ Curcumin shown to inhibit NF κ B signaling in part via downregulation of SP4; ⁴¹ COX-2 inhibitors inhibit VEGF gene expression via activation of proteasome-dependent degradation of SP4; ⁴²
<i>GRM7</i>	glutamate receptor, metabotropic 7	Mice with targeted deletion of mGluR7 show enhanced sensitivity to glucocorticoid inhibitory feedback on the HPA axis, ⁴³ which would be expected to reduce inflammatory signaling. This raises the possibility that mGluR7 signaling may support proinflammatory activity
<i>AK294384</i>	similar to Muskelin 1 (MKLN1)	Muskelin gene expression is reduced in neutrophils from patients with generalized aggressive periodontitis, a proinflammatory condition characterized by increased neutrophil IL-1b gene expression; ⁴⁴ muskelin appears to be an isoform-specific anchoring protein for the prostaglandin EP3 receptor ⁴⁵
<i>LY86</i>	lymphocyte antigen 86 aka MD-1	LY86 codes for myeloid differentiation protein MD-1, which has been recently shown to bind LPS; ⁴⁶ MD-1-null mice show impairment in LPS-induced B-cell proliferation, antibody production, and B7.2/CD86 up-regulation; ⁴⁷ inhibition of MD-1 increases expression of IL-4, IL-10 and TGF-beta and decreases IL-2, IFN-gamma and TNF-alpha expression with resultant improvement in allograft and fetal graft survival; ⁴⁸⁻⁵⁰ dorsal root ganglion neurons express the unusual combination of CD-14, TLR4, and MD-1. Blocking antibodies against TLR4 and MD-1 prevents induction of nociceptin/orphanin FQ (N/OFQ), an opioid-related peptide that is markedly up-regulated in sensory neurons in vivo following peripheral inflammation that plays a key role in pain physiology; ⁵¹ blockade of MD1 functional activity in dendritic results in elevated Treg induction in response to allogeneic stimulation (in vivo or in vitro) in the presence of LPS; ⁵² via linkage to CD14, MD-1 comprises a "danger receptor complex," and activation of this complex regulates dendritic cell surface expression of CD80/CD86, which signal T cells. ⁵³

<i>KSP37</i> aka <i>FGFBP2</i>	killer-specific secretory protein of 37 kDa aka fibroblast growth factor binding protein 2	Within leukocytes, Ksp37 expression is limited to Th1-type CD4(+) T cells, effector CD8(+) T cells, gamma-delta T cells, and CD16(+) NK cells. Most of these Ksp37-expressing cells coexpress perforin, suggesting that Ksp37 is selectively and commonly expressed in the lymphocytes that have cytotoxic potential. ⁵⁴
<i>IGSF9B</i>	immunoglobulin superfamily, member 9B	No functional data available for IGSF9B, however likely immune and/or host defense relevance is suggested by the fact that members of the immunoglobulin superfamily include cell surface antigen receptors, co-receptors and co-stimulatory molecules of the immune system, molecules involved in antigen presentation to lymphocytes, cell adhesion molecules, certain cytokine receptors and intracellular muscle proteins

Muglia et al. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. *Mol Psychiatry* 2010; 15: 589-601 ^(b)

Gene ID	Gene Name	Immune Function of Gene
<i>SMG7</i>	smg-7 homolog, nonsense mediated mRNA decay factor	No specific immune and/or host defense functions reported for SMG7; however SMG7, UPF1, SMG5 and SMG6 comprise the nonsense-mediated mRNA decay (NMD) pathway, a surveillance mechanism for eliminating mRNAs containing premature termination codons that is important in degrading retroviral DNA in eukaryotic cells; ⁵⁵ Depletion of UPF1 by siRNA dramatically reduces steady-state HIV-1 RNA and pr55(Gag), and, conversely, overexpression of UPF1 leads to significant up-regulation of HIV-1 expression at the RNA and protein synthesis levels; ⁵⁶
<i>NFKB1</i> aka <i>NFκBp50</i>	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	A database too extensive for full inclusion in this table demonstrates that the transcription factor NF-κB has multiple immune effects relevant to innate and adaptive immunity, host defense and the development of inflammatory/autoimmune diseases (including cancer); with p50 central to innate immunity via the classical NF-κB pathway; ⁵⁷⁻⁶⁶ Examples of p50 effects relevant to host defense include (but are not limited to): <ul style="list-style-type: none"> • Many bacterial pathogens (e.g. enteropathic <i>E. coli</i>) utilize a type III secretion system (T3SS) to inject effector proteins into host cells during infection that enhance virulence by degrading the p50, p65 and cRel subunits of NF-κB;⁶⁷

		<ul style="list-style-type: none">• <i>M. tuberculosis</i> promotes its own intracellular survival by inhibiting Th1 type immune responses via the ability of the bacterial protein PPE18 to block nuclear translocation of the p50 and p65 subunits of NF-κB as a result of PPE18 inducing SOCS3 masking the phosphorylation site of IκBα;⁶⁸• Varicella-zoster virus enhances its replication in melanocytic skin cells by inhibiting I-CAM producing in the center of skin lesions, in part by inhibiting TNF-alpha induced translocation of p50 to the nucleus;⁶⁹• Upon rhinovirus exposure, beta-2 adrenergic receptor agonists reduces rhinovirus titers and RNA, cytokine concentrations, and susceptibility to rhinovirus infection inhibited the activation of nuclear factor kappa-B (NF-κB) proteins, including p50 and p65, in the nucleus while increasing cytosolic concentrations of the inhibitory kappa B-alpha;⁷⁰• Apoptosis is significantly reduced in the CNS of p50-null mice following reovirus infection, but massively increased in concert with uncontrolled reovirus replication in the heart, an effect associated with marked reductions in reovirus-induced IFN-beta mRNA in the heart and partially reversed by IFN-beta administration;⁷¹• Downregulation of NFKB1 expression during Dengue infection in children is likely protective given that increased NFKB1 expression correlates with increased incidence of hemorrhagic events and with a trend toward increases in multiple other life-threatening complications;⁷²• Increased NF-κB production in response to <i>Y. Pestis</i> reduces infectious severity and mortality in animal models;⁷³• In the context of a number of infection by a number of viruses (e.g. HSV-1, HCMV), p50 appears to have conflicting effects on viral replication and spread, reducing these phenomena by stimulating apoptosis of infected cells while at the same time encouraging viral spread via herpes manipulation of the transcription factor for its own replicative purposes;^{74,75}• NF-κB protects against <i>Toxoplasma gondii</i> encephalitis via stimulation of CD8+ T cells and IFN-gamma production;⁷⁶• Polymorphisms in <i>NFKB1</i> have been associated with acute respiratory distress syndrome,^{77,78} autoimmune and inflammatory diseases in Asian populations by meta-
--	--	--

		<p>analysis,⁷⁹ and with both incidence and severity of inflammatory bowel disease in other populations in individual studies,^{80,81} and persistent viremia in HCV infection;⁸²</p> <ul style="list-style-type: none"> • NF-kappaB p50 subunit is protective during intestinal <i>Entamoeba histolytica</i> infection of the gut in animal models;⁸³
LOC654346	aka LGALS9C lectin, galactoside-binding, soluble, 9C	<p>LOC654346 codes for a protein identical, or highly similar, to galectin 9, which has widespread, highly complex, and partially paradoxical immune effects that in general appear to be anti-inflammatory via suppression of T1 and Th17 T cell immunity and enhancement of Treg;⁸⁴⁻⁸⁶ However, galectin-9 y binding to T cell Ig mucin-3 (Tim3) expressed on different cells, galectin-9 activates innate immune dendritic cells via a specific carbohydrate recognition domain (CRD), suggesting that it may enhance antigen presentation;^{87,88} via interaction with Tim3 expressed on T(H)1 cells, galectin-9, which is expressed by <i>M. tuberculosis</i>-infected macrophages, restricts intracellular bacterial growth. Tim3-galectin-9 interaction accomplishes this by leading to macrophage activation with resultant bactericidal activity induced by caspase-1-dependent IL-1β secretion;⁸⁹ galectin-9 has been shown to be an immunomodulator in the context of <i>L. major</i> infection. Galectin 9 recognizes <i>L. major</i> by binding to the <i>L. major</i>-specific polygalactosyl epitope and promotes interaction between <i>L. major</i> and macrophages;⁹⁰ galectin-9 attenuates CD8(+) T cell immunity to herpes simplex virus infection via direct inhibition of TIM3(+) CD8(+) T cells and indirectly by enhancing Foxp3(+) Treg activity;⁹¹ galectin-9 is an eosinophil chemoattractant produced by activated T cells,⁹² but also demonstrates anti-allergic effects by blocking IgE-antigen complex formation,⁹³ as well as an ability to inhibit contact hypersensitivity and psoriatic reactions;⁹⁴ by attenuating Th1 responses galectin-9 inhibits autoimmune diabetes in NOD mice,⁹⁵ and ameliorates arthritis in animal models via regulation of Fc gamma receptor expression on macrophages,⁹⁶ as well as by suppressing the generation of Th17 cells and inducing Treg;⁸⁵ galectin-9 promotes NK cell-mediated anti-tumor activity by expanding macrophages with a unique plasmacytoid cell-like phenotype (PDCA-1 and B220);⁹⁷</p>
NMNAT2	nicotinamide nucleotide adenylyltransferase 2	No specific immune and/or host defense functions reported.
LAMC2	laminin, gamma 2	Gamma 2 laminin chain production is stimulated by TNF-alpha; ⁹⁸ In response to wounding, laminin gamma2 chains are processed to smaller sizes and function to promote epithelial sheet migration over the wound bed; ^{99,100} Pathogens that avidly bind laminin as a means of

		entering host cells thereby initiating infection include <i>Aspergillus fumigates</i> , <i>Heliobacter pylori</i> , <i>Histoplasma capsulatum</i> , <i>Mycobacterium leprae</i> , <i>Paracoccidioides brasilienses</i> , rotavirus, <i>Streptococcus pyogenes</i> , <i>Treponema pallidum</i> , <i>Trypanosoma cruzi</i> ; ¹⁰¹ During inflammatory processes the enzyme neutrophil elastase digests the gamma 2 laminin chain into fragments that are chemotactic for neutrophils. ¹⁰²
<i>UGT2A2</i>	uridine 5'-diphospho glucuronosyltransferase (UDP) 2 family, polypeptide A2	Expressed primarily in nasal epithelium where it glucuronidates an array of inhaled substances. ¹⁰³ No known immune/host defense effects.
<i>UGT2A1</i>	UDP glucuronosyltransferase 2 family, polypeptide A1, complex locus	No specific immune and/or host defense functions reported for <i>UGT1A1</i> ; however, because <i>UGT2A1</i> enhances bilirubin elimination by catalyzing its conjugation glucuronic acid, ¹⁰⁴ an anti-inflammatory effect might be expected, given that increased levels of bilirubin are associated with increased levels of proinflammatory cytokines, ¹⁰⁵ in animal models, increased bilirubin associated with impaired PMN phagocytosis of <i>S. Aureus</i> , suggesting that <i>UGT21</i> activity may enhance host defense against bacterial pathogens, as a result of reducing bilirubin levels; ¹⁰⁶
<i>ATG7</i>	autophagy related 7 homolog	The autophagy degradation pathway is essential for eliminating intracellular pathogens, presenting endogenous antigens to immune cells and regulating T and B lymphocyte survival, proliferation and function ^{107,108} knocking down <i>ATG7</i> inhibits hepatitis C virus (HCV) growth via increased activity in interferon (IFN)-alpha and IFN-alpha-inducible protein 27 signaling pathways, as well as by increased caspase activation, polymerase cleavage and apoptosis of infected cells; ¹⁰⁹ <i>ATG7</i> is essential for production of myeloid and lymphoid progenitor cells; ¹¹⁰
<i>CUGBP1</i>	CUG triplet repeat, RNA binding protein 1	<i>CUGBP1</i> is a downstream effector of IFN-beta signaling in primary macrophages that is thought to play a pivotal role in innate immune responses that control acute HIV/SIV replication in the brain; ¹¹¹ <i>CUGBP1</i> participates in acute phase response in liver following LPS exposure by inducing the low molecular weight CCAAT/Enhancer binding protein (C/EBP) beta isoform, liver-enriched transcriptional inhibitory protein (LIP); ¹¹² <i>CUGBP1</i> impairs stabilization of TNF-alpha mRNA transcripts; ¹¹³
<i>NFE2L3</i>	nuclear factor (erythroid-derived 2)-like 3	<i>NFE2L3</i> modulates T cell development, based on finding that knockdown of the gene significantly increases development of T cell lymphoblastic lymphoma; ¹¹⁴ <i>NFE2L3</i> one of 20 genes upregulated in human uterine microvascular endothelial cells following administration

of IFN-gamma, other IFN-gamma induced genes include chemokines and antiviral factors;¹¹⁵ NFE2L3 involved in the control of gene expression and inflammation during cutaneous wound repair;¹¹⁶

Lewis et al. Genome-wide association study of major recurrent depression in the U.K. population. *Am J Psychiatry* 2010; 167: 949-57^(b)

Gene ID	Gene Name	Immune Function of Gene
LOC647167	encodes a protein similar to eukaryotic translation elongation factor 1 alpha 2 (<i>EF1-alpha</i>)	EF1-alpha binds and interacts with the HIV-1 Gag polyprotein, which play key functions at almost all stages of the viral life cycle. This interaction impairs <i>in vitro</i> viral RNA, a result consistent with a previously proposed model in which inhibition of translation by the accumulation of Gag serves to enhance viral spread by releasing viral RNA from polysomes, permitting the RNA to be packaged into nascent virions; ¹¹⁷ severe acute respiratory syndrome coronavirus (SARS-CoV) pathogenicity arises in part from the interaction off the viral C terminus (amino acids 251 to 422) of the N protein with human EF1-alpha which induces aggregation of EF1alpha, inhibiting protein translation and cytokinesis by blocking F-actin bundling; ¹¹⁸ EF1-alpha contributes to apoptosis during viral infection, and in response to LPS and IL-1-beta, via interaction with interferon-induced protein with tetratricopeptide repeats-1 (IFIT1), which is rapidly synthesized in response to viral infection, functions as an inhibitor of translation by binding to the eukaryotic initiation factor-3, and consequently enhances resistance activity against viral invasion to cells; ¹¹⁹ TNF-alpha down-regulates gene expression of EF1-alpha in endothelial cells; ¹²⁰
VCAN	versican	In context of cervical cancer, versican reduces number of infiltrating CD8+ T cells; ¹²¹ versican important for hyaluronan-dependent binding of monocytes to the extracellular matrix of lung fibroblasts stimulated by the viral mimetic agent, polyinosine-polycytidylic acid. These findings implicate versican in ability of viral infections to exacerbate asthma and other lung disorders; ¹²² Stimulation of mononuclear cells with GM-CSF increases the expression of versican mRNA as well as cytokine induction in these cells; ¹²³
NLGN1	neuroligin 1	NLGN1 reported to modulate immune functioning in CNS following trauma via interactions with ERK1/2 and neurexin-1-beta; ¹²⁴

LOC728275		Functionality of gene not established
BBOX1	butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1	BBOX is one of less than 1% of genes in cultured macrophages which demonstrates a change in gene expression in response to diesel exhaust particles (BBOX1 is downregulated); ¹²⁵ because gamma butyrobetaine hydroxylase catalyzes the formation of L-carnitine from gamma-butyrobetaine, the last step in the L-carnitine biosynthetic pathway, one might predict host defense relevance given evidence that L-carnitine has stimulatory effects on a number of immune functions including neutrophil activity, delayed-type hypersensitivity and the concentrations of immunoglobulins A and G (but not IgM); ¹²⁶ deficiency in L-carnitine activity/availability has been repeatedly associated with increased risk of encephalopathy in response to viral infection; ¹²⁷⁻¹²⁹ L-carnitine shown to have anti-inflammatory properties in obese diabetic patients; ¹³⁰
ATF3	activating transcription factor 3	ATF3 functions as a "hub" of the cellular adaptive-response network that modulates inflammatory responses, cellular division and apoptosis; ^{131,132} NF-kappaB, C/EBPdelta and ATF3 have been shown to form a regulatory circuit that discriminates between transient and persistent Toll-like receptor 4-induced signals, which is hypothesized to be a mechanism that enables the innate immune system to detect the duration of infection and to respond appropriately; ¹³³ ATF3 overexpression stimulates apoptotic cell death following Coxsackie virus B3 (CVB3) infection and augments CVB3 infection-induced eIF2alpha phosphorylation. However, ATF3 overexpression does not affect viral protein production, but rather promotes virus progeny release; ¹³⁴ via interaction with a cis-regulatory site on the IFN-gamma gene, ATF3 reduces NK cell activity against murine cytomegalovirus (MCMV), with a resultant increase in viral pathology. Correspondingly, ATF3null mice show exhibit decreased hepatic viral load and reduced liver histopathology upon challenge with MCMV; ¹³⁵ ATF3 is one of a small set of genes upregulated by adenovirus infection prior to commencement of viral gene expression; ^{136,137} ATF3 is required for the interferon-induced serine/threonine protein kinase (PKR) to induce apoptosis of virally infected cells; ¹³⁸ ATF3 is also functionally important in mediating the pro-apoptotic effects of the proinflammatory p38 MAPK signaling pathway; ¹³⁹ ATF3 production is stimulated by IL-12, IL-18 and IFN-alpha. Conflicting data suggest ATF3 may enhance or repress the development of a Th1 cytokine profile in CD+ T cells; ^{140,141} Blocking ATF3 reduces IL-6 production in response to TLR stimulation; ¹⁴² ATF3 is induced by, and induces TGF-beta and is essential for activation of TGF-beta target genes; ¹⁴³ ATF3 induces STAT1; ¹⁴⁴ ATF3 enhances inflammatory responses to grafted islet cells promoting rejection; ¹⁴⁵ ATF3 is required for mast cell maturation and function; ¹³² with heat shock transcription factor-1, ATF3 is necessary for ability of febrile temperatures to suppress IL-6

		production; ¹⁴⁶ ATF3 acts as a transcriptional repressor of TLR4 signaling, ¹⁴⁷ leading to transcriptional repression of TNF-alpha production in macrophages; ¹⁴⁸ LPS-induced expression of matrix metalloproteinases in human monocytes is suppressed by IFN-gamma via superinduction of ATF-3; ¹⁴⁹ in a mouse model of human asthma, ATF3-deficiency significantly increases airway hyperresponsiveness, pulmonary eosinophilia, and enhances chemokine and Th2 cytokine responses in lung tissue and in lung-derived CD4(+) lymphocytes; ¹⁵⁰ ATF is increased by COX-2 activity; ¹⁵¹
<i>C14orf49</i>	<u>aka</u> NET53 and nesprin-3	No specific immune and/or host defense functions reported
<i>LOC440742</i>	hypothetical LOC440742	Functionality of gene not established
<i>LOC338805</i>	LOC338805	Functionality of gene not established
<i>ACYP2</i>	acylphosphatase 2, muscle type	No specific immune and/or host defense functions reported



Terracciono et al. Genome-wide association scan of trait depression. *Biol Psychiatry* 2010; 68: 811-17 ^(b)

Gene ID	Gene Name	Immune Function of Gene
<i>RORA</i>	retinoic acid receptor-related orphan receptor alpha	RORA, in combination with ROR-gamma, is essential for differentiation of naïve T cells in to Th17 phenotype, and RORA blockade prevents Th17 differentiation; ¹⁵²⁻¹⁵⁴ knocking down RORA receptor activity in mice is associated with increased T cell IFN-gamma production following T-cell receptor stimulation, with increased TNF-alpha and IL-6 production upon activation of macrophages or mast cells, with increased IgG antibodies following immunization with a T-Cell dependent antigen and with increased CD8+ T cell cytotoxic activity against <i>L. monocytogenes</i> infected cells; ¹⁵⁵ RORA one of 22 genes upregulated by hepatitis B virus (HBV) infection and downregulated by treatment of HBV-infected cells with lamivudine; ¹⁵⁶ RORA has anti-inflammatory effect in experimental autoimmune uveoretinitis; ^{157,158} allelic differences in RORA are associated with circulating levels of CRP in a meta-analysis of 15 GWAS studies; ¹⁵⁹ RORA gene expression profoundly inhibited by LPS

		in humans in vivo; ¹⁶⁰ in resting astrocytes RORA essential to maintain basal IL-6 levels, however following inflammatory stimulation, RORA suppresses astrocytic IL-6 production; ¹⁶¹ stable transfection experiments have demonstrated that overexpression of RORA specifically increases endogenous fibrinogen-beta mRNA levels, with immunoprecipitation studies showing that the human fibrinogen-beta gene is a direct target for RORA; ¹⁶² acting via inhibition of NFκB, RORA suppresses TNF-alpha-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells; ¹⁶³
<i>SLFN12L</i>	Schlafen family member 12-like	No immune and/or host defense functions reported specifically for <i>SLFN12</i> ; however, mice with a functional impairment in a related Schlafen family member gene (<i>SLFN2</i>) show enhanced susceptibility to bacterial and viral infection and diminished numbers of T cells and inflammatory monocytes that fail to proliferate after infection; ¹⁶⁴ Genes from the Schlafen family are differentially expressed during, and profoundly influence, thymocyte development; ¹⁶⁵ Schlafen family genes also show a strong association with circulating NK cell levels; ¹⁶⁶
<i>CDH18</i>	Cadherin 18, type 2	No immune and/or host defense functions reported specifically for <i>CHD18</i> ; however extensive data link other cadherins (especially E-cadherin [CDH1]) to host defense. For example, multiple pathogens (e.g. <i>L. monocytogenes</i> , <i>C. botulinum</i> <i>H. pylori</i> , <i>anthrax</i> , <i>Enterotoxigenic Bacteroides</i> , <i>C. rodentium</i>) secrete factors that enhance virulence by interacting with E-cadherin to disrupt cellular junctions thus promoting entry of pathogen or toxins into host tissues; ¹⁶⁷⁻¹⁷³ cleavage of E-cadherin by calpains generated in response to TLR2 mediated Ca(2+) fluxes promote the transepithelial migration of PMNs within the lung during <i>P. aeruginosa</i> infection; ¹⁷⁴ mechanisms that regulate the retention of tissue-resident memory T cells include transforming growth factor-β (TGF-β)-mediated induction of the E-cadherin receptor CD103 and downregulation of the chemokine receptor CCR7. These pathways enhance protection in internal organs, such as the nervous system, and in the barrier tissues-the mucosa and skin. Memory T cells that reside at these surfaces provide a first line of defense against subsequent infection, and defining the factors that regulate their development is critical to understanding organ-based immunity. ¹⁷⁵
<i>EIF3F</i>	eukaryotic translation initiation factor 3, subunit F	EIF3F is a protein synthesis initiation factor that potently inhibits HIV-1 replication; ^{176,177} EIF3F is a component of the nuclear interactome of the HIV-1 encoded regulatory protein Tat, which is essential for HIV-1 replication and primarily orchestrates HIV-1 provirus transcriptional regulation; ⁵ EIF3F is required for initiation of HCV RNA translation in host cells and its

		<p>induction is essential for the ability of iron to increase HCV expression;¹⁷⁸⁻¹⁸¹ In cells infected with poliovirus, cellular mRNA fails to bind to ribosomes, and synthesis of the majority of cellular proteins ceases, a pathological process dependent upon viral 2Apro cleavage of EIF3F;^{182,183} EIF3F-induced deubiquitination essential for activation of Notch signaling pathway.¹⁸⁴ The Notch pathway has numerous effects relevant to inflammation/host-pathogen defense,¹⁸⁵⁻¹⁸⁷ including 1) activation of IFN-gamma production in CD4+ T cells and IFN-alpha production in dendritic cells in response to HSV-2 infection;¹⁸⁸; 2) promotion of Kaposi's sarcoma-associated herpesvirus latency (with increased cancer risk) via induction of RBP-Jk, the master regulator of the Notch signaling pathway;¹⁸⁹; 3) promotion of herpes virus transition from latency to activation status;¹⁹⁰ 3) promotion of Th17 activity and protective granuloma formation in response to <i>M. tuberculosis</i> infection via TLR9 signaling;¹⁹¹ 4) modulation of either a pathogen promoting Th2 or disease-controlling Th1 CD4+ T cell response <i>L. major</i> infection;¹⁹² 5) promotion of more competent, less pathogenic antiviral response to RSV infection;¹⁹³ 6) cooptation by gamma herpesviruses to establish lifelong infection;¹⁹⁴ 7) efficient induction of cytotoxic CD+ T cells and increased ability of dendritic cells to induce cytotoxic CD8 cells;¹⁹⁵ 8) regulation of IL-10 IFN-gamma-secreting CD4(+) T cells that suppress cytotoxic CD8+ cells;¹⁹⁶ 9) induction of Th2 type T cell responses at the expense of Th1 responses, in part by regulating the transcription factors T-bet and GATA-3;¹⁹⁷ 10) activation of microglia to produce proinflammatory cytokines in response to cerebral ischemia,¹⁹⁸ 11) induction of inflammatory mediators and apoptosis in context of renal ischemia/reperfusion injury;¹⁹⁹ 12) retention and survival of T cells in areas of arterial vessel wall inflammation;²⁰⁰</p>
<i>FAM155A</i>	FAM155A family with sequence similarity 155, member A	Functionality of gene not established
<i>CDH13</i>	Cadherin 13 (heart)	SNP variants within CDH13 have been shown to interact with PTPN22 1858T to increase risk of developing autoimmunity (rheumatoid arthritis); ²⁰¹ for information on cadherins more generally see discussion under <i>CDH18</i> above
<i>ITGB1</i>	integrin, beta 1	Integrin beta-1 is a primary pathway whereby several viruses (e.g. Hantaan virus, cytomegalovirus) gain access to host cells, ^{202,203} and blockade of ITGB1 enhances host survival following infection with viruses that utilize ITGB1 as a means of cellular entry; ²⁰² integrin beta 1 plays an important role in the ability of a number of bacterial species (e.g. <i>Y. pseudotuberculosis</i> , <i>Y. enterocolitica</i> , <i>S. pyogenes</i> , <i>B. burgdorferi</i>) to gain entry into host

		<p>epithelial/endothelial cells and thereby commence infection;²⁰⁴⁻²⁰⁷ ITGB1 contributes to host defense against <i>S. pneumonia</i> by allowing leukocytes direct access to lung bronchioles early in the infectious process;²⁰⁸ blockade of integrin beta-1 significantly reduces TNF-alpha production by monocytes, peritoneal and alveolar macrophages in response to heat-killed <i>S. aureus</i>;²⁰⁹ integrin beta-1 contributes to development of non-T cell-dependent extrafollicular antigen-specific splenic plasmablasts important for protection against intracellular bacteria such as I pathogens such as <i>Ehrlichia muris</i>;²¹⁰ human CMV infection may increase risk of cardiovascular disease by increasing endothelial cell proliferation, motility, and capillary tube formation in dependence upon binding to and signaling through the beta(1) and beta(3) integrins and the epidermal growth factor receptor, via their ability to activate the phosphatidylinositol 3-kinase and the mitogen-activated protein kinase signaling pathways;²¹¹ human CMV ability to activate IFN-alpha signaling is partially dependent on viral interactions with integrin beta-1, whereas HCMV induced proinflammatory cytokine production is TLR2, but not ITGB1-dependent;²¹¹ binding interactions of bacteria intimin with epithelial integrin beta-1 are essential for infection of human colonic epithelium by Shiga toxin-producing Enterohemorrhagic <i>E. coli</i>;²¹² anopheline antiplatelet protein (AAPP) isolated from the saliva of <i>Anopheles stephensi</i>, a human malaria vector mosquito, exhibits a strong and specific inhibitory activity toward collagen-induced platelet aggregation (allowing blood feeding to proceed effectively) that depends in part upon integrin beta-1;²¹³ integrin beta-1 required for long-term retention of memory CD4+ T cells in bone marrow following <i>L. monocytogenes</i> infection, although integrin beta-1 is not required for maintenance of long-term pathogen-specific memory CD+ T cells;²¹⁴ stimulation of the TLR4 by LPS activates PI3K/AKT signaling and promotes downstream beta-1 integrin function, which has been implicated in increased cancer cell adhesiveness and metastatic potential;²¹⁵</p>
<p><i>GRM8</i></p>	<p>glutamate receptor, metabotropic 8</p>	<p>GRM8 (a type III mGlu) has been identified as a vulnerability gene for inflammatory bowel disease (Crohn's) in more than one population sample,²¹⁶ suggesting a link between GRM8 and inflammatory functioning; GRM8 activation reduces hyperalgesia in response to inflammatory stimulation in animal models;²¹⁷ in response to inflammatory signaling, polymorphonuclear leukocytes release glutamate that decreases human brain endothelial barrier function via reductions in phosphorylated vasodilator-stimulated phosphoprotein,²¹⁸ suggesting that type III mGlu signaling is involved in PMN migration in response to infection; type III mGlu stimulation mediates the excitotoxic effects of the proinflammatory mediators homocysteine and homocysteic acid;²¹⁹ type III mGlu stimulation blocks TLR4-activated microglia inhibition of oligodendrocyte progenitor cells (which is driven by microglia TNF-alpha/IL-6 production);²²⁰</p>

(a) = a study that finds genome-wide level significance for associations between allelic variants and depression; (b) = a study that failed to find genome-wide level significance for associations between allelic variants and depression

References

1. Jeong SM, Lee C, Lee SK, Kim J, Seong RH: The SWI/SNF chromatin-remodeling complex modulates peripheral T cell activation and proliferation by controlling AP-1 expression. *J Biol Chem* 2010, **285**:2340-2350.
2. Cullen SJ, Ponnappan S, Ponnappan U: Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes. *Mol Immunol* 2009, **47**:600-605.
3. Osipovich OA, Subrahmanyam R, Pierce S, Sen R, Oltz EM: Cutting edge: SWI/SNF mediates antisense Igh transcription and locus-wide accessibility in B cell precursors. *J Immunol* 2009, **183**:1509-1513.
4. Ramirez-Carrozzi VR, Nazarian AA, Li CC, Gore SL, Sridharan R, Imbalzano AN, *et al*: Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. *Genes Dev* 2006, **20**:282-296.
5. Gautier VW, Gu L, O'Donoghue N, Pennington S, Sheehy N, Hall WW: In vitro nuclear interactome of the HIV-1 Tat protein. *Retrovirol* 2009, **6**:47.
6. Easley R, Carpio L, Dannenberg L, Choi S, Alani D, Van Duyne R, *et al*: Transcription through the HIV-1 nucleosomes: effects of the PBAF complex in Tat activated transcription. *Virology* 2010, **405**:322-333.
7. Mahmoudi T, Parra M, Vries RG, Kauder SE, Verrijzer CP, Ott M, *et al*: The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. *J Biol Chem* 2006, **281**:19960-19968.
8. Iba H, Mizutani T, Ito T: SWI/SNF chromatin remodelling complex and retroviral gene silencing. *Rev Med Virol* 2003, **13**:99-110.
9. Van Duyne R, Guendel I, Narayanan A, Gregg E, Shafagati N, Tyagi M, *et al*: Varying Modulation of HIV-1 LTR Activity by BAF Complexes. *J Mol Biol* 2011.

10. Lesbats P, Botbol Y, Chevereau G, Vaillant C, Calmels C, Arneodo A, *et al*: Functional coupling between HIV-1 integrase and the SWI/SNF chromatin remodeling complex for efficient in vitro integration into stable nucleosomes. *Plos Pathog* 2011, **7**:e1001280.
11. Easley R, Carpio L, Guendel I, Klase Z, Choi S, Kehn-Hall K, *et al*: Human T-lymphotropic virus type 1 transcription and chromatin-remodeling complexes. *J Virol* 2010, **84**:4755-4768.
12. Sorin M, Cano J, Das S, Mathew S, Wu X, Davies KP, *et al*: Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication. *Plos Pathog* 2009, **5**:e1000463.
13. Yan Z, Cui K, Murray DM, Ling C, Xue Y, Gerstein A, *et al*: PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. *Genes Dev* 2005, **19**:1662-1667.
14. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C: The IFITM proteins inhibit HIV-1 infection. *J Virol* 2011, **85**:2126-2137.
15. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, *et al*: Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. *Plos Pathog* 2011, **7**:e1001258.
16. Cui K, Taylor P, Liu H, Chen X, Ozato K, Zhao K: The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming. *Mol Cell Biol* 2004, **24**:4476-4486.
17. Pattenden SG, Klose R, Karaskov E, Bremner R: Interferon-gamma-induced chromatin remodeling at the CIITA locus is BRG1 dependent. *EMBO J* 2002, **21**:1978-1986.
18. Zhang Y, Cheng MB, Zhang YJ, Zhong X, Dai H, Yan L, *et al*: A switch from hBrm to Brg1 at IFNgamma-activated sequences mediates the activation of human genes. *Cell Res* 2010, **20**:1345-1360.

19. Brockmann D, Lehmkuhler O, Schmucker U, Esche H: The histone acetyltransferase activity of PCAF cooperates with the brahma/SWI2-related protein BRG-1 in the activation of the enhancer A of the MHC class I promoter. *Gene* 2001, **277**:111-120.
20. Cha S, Seo T: hSNF5 is required for human papillomavirus E2-driven transcriptional activation and DNA replication. *InterVirol* 2011, **54**:66-77.
21. Sun YG, Wang XW, Yang SM, Zhou G, Wang WQ, Wang HB, *et al*: Inhibition of nucleostemin upregulates CDX2 expression in HT29 cells in response to bile acid exposure: implications in the pathogenesis of Barrett's esophagus. *J Gastrointest Surg* 2009, **13**:1430-1439.
22. Nguyen HT, Dalmasso G, Powell KR, Yan Y, Bhatt S, Kalman D, *et al*: Pathogenic bacteria induce colonic PepT1 expression: an implication in host defense response. *Gastroenterol* 2009, **137**:1435-1447 e1431-1432.
23. Ericsson A, Kotarsky K, Svensson M, Sigvardsson M, Agace W: Functional characterization of the CCL25 promoter in small intestinal epithelial cells suggests a regulatory role for caudal-related homeobox (Cdx) transcription factors. *J Immunol* 2006, **176**:3642-3651.
24. Vicari AP, Figueroa DJ, Hedrick JA, Foster JS, Singh KP, Menon S, *et al*: TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. *Immunity* 1997, **7**:291-301.
25. Zaballos A, Gutierrez J, Varona R, Ardavin C, Marquez G: Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. *J Immunol* 1999, **162**:5671-5675.
26. Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z, *et al*: Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. *J Immunol* 2000, **164**:2851-2856.

27. Lisik W, Tejpal N, Gong Y, Skelton TS, Ganachari M, Bremer EG, *et al*: Down regulation of genes involved in T cell polarity and motility during the induction of heart allograft tolerance by allochimeric MHC I. *PLoS One* 2009, **4**:e8020.
28. Welin A, Raffetseder J, Eklund D, Stendahl O, Lerm M: Importance of Phagosomal Functionality for Growth Restriction of Mycobacterium tuberculosis in Primary Human Macrophages. *J Innate Immun* 2011.
29. Xu L, Shen X, Bryan A, Banga S, Swanson MS, Luo ZQ: Inhibition of host vacuolar H⁺-ATPase activity by a Legionella pneumophila effector. *Plos Pathog* 2010, **6**:e1000822.
30. Chong A, Wehrly TD, Nair V, Fischer ER, Barker JR, Klose KE, *et al*: The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression. *Infect Immun* 2008, **76**:5488-5499.
31. Ran H, Hassett DJ, Lau GW: Human targets of Pseudomonas aeruginosa pyocyanin. *Proc Natl Acad Sci U S A* 2003, **100**:14315-14320.
32. Marjuki H, Gornitzky A, Marathe BM, Ilyushina NA, Aldridge JR, Desai G, *et al*: Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion. *Cell Microbiol* 2011, **13**:587-601.
33. Muller KH, Kainov DE, El Bakkouri K, Saelens X, De Brabander JK, Kittel C, *et al*: The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. *Br J Pharmacol* 2011.
34. Suzuki T, Yamaya M, Sekizawa K, Hosoda M, Yamada N, Ishizuka S, *et al*: Bafilomycin A(1) inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1. *Am J Physiol Lung Cell Mol Physiol* 2001, **280**:L1115-1127.
35. Kwong C, Gilman-Sachs A, Beaman K: Tumor-associated a2 vacuolar ATPase acts as a key mediator of cancer-related inflammation by inducing pro-tumorigenic properties in monocytes. *J Immunol* 2011, **186**:1781-1789.

36. Ntrivalas E, Derks R, Gilman-Sachs A, Kwak-Kim J, Levine R, Beaman K: Novel role for the N-terminus domain of the $\alpha 2$ isoform of vacuolar ATPase in interleukin-1 β production. *Hum Immunol* 2007, **68**:469-477.
37. Ntrivalas E, Gilman-Sachs A, Kwak-Kim J, Beaman K: The N-terminus domain of the $\alpha 2$ isoform of vacuolar ATPase can regulate interleukin-1 β production from mononuclear cells in co-culture with JEG-3 choriocarcinoma cells. *Am J Reprod Immunol* 2007, **57**:201-209.
38. Ntrivalas E, Levine R, Kwong C, Gilman-Sachs A, Beaman K: The $\alpha 2$ isoform of vacuolar ATPase is a modulator of implantation and feto-maternal immune tolerance in early pregnancy. *J Reprod Immunol* 2010, **85**:106-111.
39. Majello B, De Luca P, Hagen G, Suske G, Lania L: Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. *Nucleic Acids Res* 1994, **22**:4914-4921.
40. Joubert BR, Lange EM, Franceschini N, Mwapasa V, North KE, Meshnick SR: A whole genome association study of mother-to-child transmission of HIV in Malawi. *Genome Med* 2010, **2**:17.
41. Jutooru I, Chadalapaka G, Lei P, Safe S: Inhibition of NF κ B and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. *J Biol Chem* 2010, **285**:25332-25344.
42. Abdelrahim M, Safe S: Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. *Mol Pharmacol* 2005, **68**:317-329.
43. Mitsukawa K, Mombereau C, Lotscher E, Uzunov DP, van der Putten H, Flor PJ, *et al*: Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. *Neuropsychopharmacol* 2006, **31**:1112-1122.

44. Kubota T, Morozumi T, Shimizu K, Sugita N, Kobayashi T, Yoshie H: Differential gene expression in neutrophils from patients with generalized aggressive periodontitis. *J Periodontal Res* 2001, **36**:390-397.
45. Hasegawa H, Katoh H, Fujita H, Mori K, Negishi M: Receptor isoform-specific interaction of prostaglandin EP3 receptor with muskelin. *Biochem Biophys Res Commun* 2000, **276**:350-354.
46. Mengwasser KE, Bryant CE, Gay NJ, Gangloff M: LPS ligand and culture additives improve production of monomeric MD-1 and 2 in *Pichia pastoris* by decreasing aggregation and intermolecular disulfide bonding. *Protein Expr Purif* 2011, **76**:173-183.
47. Nagai Y, Shimazu R, Ogata H, Akashi S, Sudo K, Yamasaki H, *et al*: Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. *Blood* 2002, **99**:1699-1705.
48. Lee SW, Wang JY, Hsieh YC, Wu YJ, Ting HW, Wu LS: Association of single nucleotide polymorphisms of MD-1 gene with pediatric and adult asthma in the Taiwanese population. *J Microbiol Immunol Infect* 2008, **41**:445-449.
49. Miura Y, Shimazu R, Miyake K, Akashi S, Ogata H, Yamashita Y, *et al*: RP105 is associated with MD-1 and transmits an activation signal in human B cells. *Blood* 1998, **92**:2815-2822.
50. Clark DA, Yu G, Arck PC, Levy GA, Gorczynski RM: MD-1 is a critical part of the mechanism causing Th1-cytokine-triggered murine fetal loss syndrome. *Am J Reprod Immunol* 2003, **49**:297-307.
51. Acosta C, Davies A: Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons. *J Neurosci Res* 2008, **86**:1077-1086.
52. Gorczynski RM, Kai Y, Miyake K: MD1 expression regulates development of regulatory T cells. *J Immunol* 2006, **177**:1078-1084.

53. Gorczynski RM, Chen Z, Clark DA, Hu J, Yu G, Li X, *et al*: Regulation of gene expression of murine MD-1 regulates subsequent T cell activation and cytokine production. *J Immunol* 2000, **165**:1925-1932.
54. Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, *et al*: A novel serum protein that is selectively produced by cytotoxic lymphocytes. *J Immunol* 2001, **166**:6404-6412.
55. Withers JB, Beemon KL: The structure and function of the Rous sarcoma virus RNA stability element. *J Cell Biochem* 2011.
56. Ajamian L, Abrahamyan L, Milev M, Ivanov PV, Kulozik AE, Gehring NH, *et al*: Unexpected roles for UPF1 in HIV-1 RNA metabolism and translation. *RNA* 2008, **14**:914-927.
57. Droebner K, Klein B, Paxian S, Schmid R, Stitz L, Planz O: The alternative NF-kappaB signalling pathway is a prerequisite for an appropriate immune response against lymphocytic choriomeningitis virus infection. *Viral Immunol* 2010, **23**:295-308.
58. Blackwell TS, Christman JW: The role of nuclear factor-kappa B in cytokine gene regulation. *Am J Respir Cell Mol Biol* 1997, **17**:3-9.
59. Yamamoto K, Arakawa T, Ueda N, Yamamoto S: Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. *J Biol Chem* 1995, **270**:31315-31320.
60. Osborn L, Kunkel S, Nabel GJ: Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. *Proc Natl Acad Sci U S A* 1989, **86**:2336-2340.
61. Lee JI, Burckart GJ: Nuclear factor kappa B: important transcription factor and therapeutic target. *J Clin Pharmacol* 1998, **38**:981-993.
62. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB: NF-kappaB addiction and its role in cancer: 'one size does not fit all'. *Oncogene* 2011, **30**:1615-1630.

63. Imbeault M, Ouellet M, Giguere K, Bertin J, Belanger D, Martin G, *et al*: Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. *J Virol* 2011, **85**:2189-2200.
64. Souvannavong V, Saidji N, Chaby R: Lipopolysaccharide from *Salmonella enterica* activates NF-kappaB through both classical and alternative pathways in primary B Lymphocytes. *Infect Immun* 2007, **75**:4998-5003.
65. Fei M, Bhatia S, Oriss TB, Yarlagadda M, Khare A, Akira S, *et al*: TNF-alpha from inflammatory dendritic cells (DCs) regulates lung IL-17A/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection. *Proc Natl Acad Sci U S A* 2011, **108**:5360-5365.
66. Mizgerd JP, Lupa MM, Spieker MS: NF-kappaB p50 facilitates neutrophil accumulation during LPS-induced pulmonary inflammation. *BMC Immunol* 2004, **5**:10.
67. Pearson JS, Riedmaier P, Marches O, Frankel G, Hartland EL: A type III effector protease NleC from enteropathogenic *Escherichia coli* targets NF-kappaB for degradation. *Mol Microbiol* 2011, **80**:219-230.
68. Nair S, Pandey AD, Mukhopadhyay S: The PPE18 protein of *Mycobacterium tuberculosis* inhibits NF-kappaB/rel-mediated proinflammatory cytokine production by upregulating and phosphorylating suppressor of cytokine signaling 3 protein. *J Immunol* 2011, **186**:5413-5424.
69. El Mjiyad N, Bontems S, Gloire G, Horion J, Vandevenne P, Dejardin E, *et al*: Varicella-zoster virus modulates NF-kappaB recruitment on selected cellular promoters. *J Virol* 2007, **81**:13092-13104.
70. Yamaya M, Nishimura H, Hatachi Y, Yoshida M, Fujiwara H, Asada M, *et al*: Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. *Eur J Pharmacol* 2011, **650**:431-444.

71. O'Donnell SM, Hansberger MW, Connolly JL, Chappell JD, Watson MJ, Pierce JM, *et al*: Organ-specific roles for transcription factor NF-kappaB in reovirus-induced apoptosis and disease. *J Clin Invest* 2005, **115**:2341-2350.
72. de Kruijff MD, Setiati TE, Mairuhu AT, Koraka P, Aberson HA, Spek CA, *et al*: Differential gene expression changes in children with severe dengue virus infections. *PLoS Negl Trop Dis* 2008, **2**:e215.
73. Liu T, Agar SL, Sha J, Chopra AK: Deletion of Braun lipoprotein gene (lpp) attenuates Yersinia pestis KIM/D27 strain: role of Lpp in modulating host immune response, NF-kappaB activation and cell death. *Microb Pathog* 2010, **48**:42-52.
74. Taddeo B, Zhang W, Lakeman F, Roizman B: Cells lacking NF-kappaB or in which NF-kappaB is not activated vary with respect to ability to sustain herpes simplex virus 1 replication and are not susceptible to apoptosis induced by a replication-incompetent mutant virus. *J Virol* 2004, **78**:11615-11621.
75. He B, Weber GF: Synergistic activation of the CMV promoter by NF-kappaB P50 and PKG. *Biochem Biophys Res Commun* 2004, **321**:13-20.
76. Harris TH, Wilson EH, Tait ED, Buckley M, Shapira S, Caamano J, *et al*: NF-kappaB1 contributes to T cell-mediated control of Toxoplasma gondii in the CNS. *J Neuroimmunol* 2010, **222**:19-28.
77. Bajwa EK, Cremer PC, Gong MN, Zhai R, Su L, Thompson BT, *et al*: An NFKB1 Promoter Insertion/Deletion Polymorphism Influences Risk and Outcome in Acute Respiratory Distress Syndrome among Caucasians. *PLoS One* 2011, **6**:e19469.
78. Adamzik M, Frey UH, Rieman K, Sixt S, Beiderlinden M, Siffert W, *et al*: Insertion/deletion polymorphism in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome. *Intensive Care Med* 2007, **33**:1199-1203.

79. Zou YF, Wang F, Feng XL, Tao JH, Zhu JM, Pan FM, *et al*: Association of NFKB1 - 94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. *Tissue Antigens* 2011, **77**:9-17.
80. Takedatsu H, Taylor KD, Mei L, McGovern DP, Landers CJ, Gonsky R, *et al*: Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation. *Gut* 2009, **58**:60-67.
81. Szamosi T, Lakatos PL, Szilvasi A, Lakatos L, Kovacs A, Molnar T, *et al*: The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients. *Dig Dis Sci* 2009, **54**:351-359.
82. Saito T, Ji G, Shinzawa H, Okumoto K, Hattori E, Adachi T, *et al*: Genetic variations in humans associated with differences in the course of hepatitis C. *Biochem Biophys Res Commun* 2004, **317**:335-341.
83. Cho KN, Becker SM, Houpt ER: The NF-kappaB p50 subunit is protective during intestinal *Entamoeba histolytica* infection of 129 and C57BL/6 mice. *Infect Immun* 2010, **78**:1475-1481.
84. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, *et al*: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. *Nat Immunol* 2005, **6**:1245-1252.
85. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, *et al*: Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. *Clin Immunol* 2008, **127**:78-88.
86. Wang F, Wan L, Zhang C, Zheng X, Li J, Chen ZK: Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. *Immunobiology* 2009, **214**:342-349.

87. Li Y, Feng J, Geng S, Wei H, Chen G, Li X, *et al*: The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. *Mol Immunol* 2011, **48**:670-677.
88. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, *et al*: Galectin-9 increases Tim-3⁺ dendritic cells and CD8⁺ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. *J Immunol* 2008, **181**:7660-7669.
89. Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, *et al*: Tim3 binding to galectin-9 stimulates antimicrobial immunity. *J Exp Med* 2010, **207**:2343-2354.
90. Pelletier I, Hashidate T, Urashima T, Nishi N, Nakamura T, Futai M, *et al*: Specific recognition of Leishmania major poly-beta-galactosyl epitopes by galectin-9: possible implication of galectin-9 in interaction between L. major and host cells. *J Biol Chem* 2003, **278**:22223-22230.
91. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, Rouse BT: Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. *Plos Pathog* 2010, **6**:e1000882.
92. Sato M, Nishi N, Shoji H, Seki M, Hashidate T, Hirabayashi J, *et al*: Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. *Glycobiology* 2002, **12**:191-197.
93. Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K, *et al*: Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. *J Biol Chem* 2009, **284**:32344-32352.
94. Niwa H, Satoh T, Matsushima Y, Hosoya K, Saeki K, Niki T, *et al*: Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. *Clin Immunol* 2009, **132**:184-194.

95. Chou FC, Shieh SJ, Sytwu HK: Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. *Eur J Immunol* 2009, **39**:2403-2411.
96. Arikawa T, Watanabe K, Seki M, Matsukawa A, Oomizu S, Sakata KM, *et al*: Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages. *Clin Immunol* 2009, **133**:382-392.
97. Nobumoto A, Oomizu S, Arikawa T, Katoh S, Nagahara K, Miyake M, *et al*: Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. *Clin Immunol* 2009, **130**:322-330.
98. Zboralski D, Warscheid B, Klein-Scory S, Malas MB, Becker H, Bockmann M, *et al*: Uncoupled responses of Smad4-deficient cancer cells to TNFalpha result in secretion of monomeric laminin-gamma2. *Mol Cancer* 2010, **9**:65.
99. Chang YC, Sabourin CL, Lu SE, Sasaki T, Svoboda KK, Gordon MK, *et al*: Upregulation of gamma-2 laminin-332 in the mouse ear vesicant wound model. *J Biochem Mol Toxicol* 2009, **23**:172-184.
100. Fitsialos G, Bourget I, Augier S, Ginouves A, Rezzonico R, Odorisio T, *et al*: HIF1 transcription factor regulates laminin-332 expression and keratinocyte migration. *J Cell Sci* 2008, **121**:2992-3001.
101. Scheele S, Nystrom A, Durbeej M, Talts JF, Ekblom M, Ekblom P: Laminin isoforms in development and disease. *J Mol Med (Berl)* 2007, **85**:825-836.
102. Mydel P, Shipley JM, Adair-Kirk TL, Kelley DG, Broekelmann TJ, Mecham RP, *et al*: Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. *J Biol Chem* 2008, **283**:9513-9522.
103. Sneitz N, Court MH, Zhang X, Laajanen K, Yee KK, Dalton P, *et al*: Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional

- characterization in comparison with UGT2A1 and UGT2A3. *Pharmacogenet Genomics* 2009.
104. Saito A, Kawamoto M, Kamatani N: Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects. *J Hum Genet* 2009, **54**:317-323.
 105. Kimura F, Miyazaki M, Suwa T, Sugiura T, Shinoda T, Itoh H, *et al*: Anti-inflammatory response in patients with obstructive jaundice caused by biliary malignancy. *J Gastroenterol Hepatol* 2001, **16**:467-472.
 106. Roughneen PT, Drath DB, Kulkarni AD, Kumar SC, Andrassy RJ, Rowlands BJ: Inflammatory cell function in young rodents with experimental cholestasis: investigations of functional deficits, their etiology, and their reversibility. *J Pediatr Surg* 1989, **24**:668-673.
 107. Fujitani Y, Ebato C, Uchida T, Kawamori R, Watada H: beta-cell autophagy: A novel mechanism regulating beta-cell function and mass: Lessons from beta-cell-specific Atg7-deficient mice. *Islets* 2009, **1**:151-153.
 108. Jia W, Pua HH, Li QJ, He YW: Autophagy regulates endoplasmic reticulum homeostasis and calcium mobilization in T lymphocytes. *J Immunol* 2011, **186**:1564-1574.
 109. Shrivastava S, Raychoudhuri A, Steele R, Ray R, Ray RB: Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. *Hepatology* 2011, **53**:406-414.
 110. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, *et al*: The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. *J Exp Med* 2011, **208**:455-467.
 111. Dudaronek JM, Barber SA, Clements JE: CUGBP1 is required for IFNbeta-mediated induction of dominant-negative CEBPbeta and suppression of SIV replication in macrophages. *J Immunol* 2007, **179**:7262-7269.

112. Welm AL, Mackey SL, Timchenko LT, Darlington GJ, Timchenko NA: Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/enhancer binding protein alpha mRNA. *J Biol Chem* 2000, **275**:27406-27413.
113. Zhang L, Lee JE, Wilusz J, Wilusz CJ: The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. *J Biol Chem* 2008, **283**:22457-22463.
114. Chevillard G, Paquet M, Blank V: Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma. *Blood* 2011, **117**:2005-2008.
115. Kitaya K, Yasuo T, Yamaguchi T, Fushiki S, Honjo H: Genes regulated by interferon-gamma in human uterine microvascular endothelial cells. *Int J Mol Med* 2007, **20**:689-697.
116. Braun S, Hanselmann C, Gassmann MG, auf dem Keller U, Born-Berclaz C, Chan K, *et al*: Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. *Mol Cell Biol* 2002, **22**:5492-5505.
117. Cimarelli A, Luban J: Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. *J Virol* 1999, **73**:5388-5401.
118. Zhou B, Liu J, Wang Q, Liu X, Li X, Li P, *et al*: The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1alpha. *J Virol* 2008, **82**:6962-6971.
119. Li HT, Su YP, Cheng TM, Xu JM, Liao J, Chen JC, *et al*: The interaction between interferon-induced protein with tetratricopeptide repeats-1 and eukaryotic elongation factor-1A. *Molecular Cellular Biochemistry* 2010, **337**:101-110.

120. Liliensiek B, Rocha M, Umansky V, Benner A, Lin J, Ziegler R, *et al*: Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status--a study in ex vivo-isolated endothelial cells. *Blood* 1998, **92**:3394-3404.
121. Gorter A, Zijlmans HJ, van Gent H, Trimbos JB, Fleuren GJ, Jordanova ES: Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. *Mod Pathol* 2010, **23**:1605-1615.
122. Potter-Perigo S, Johnson PY, Evanko SP, Chan CK, Braun KR, Wilkinson TS, *et al*: Polyinosine-polycytidylic acid stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion. *Am J Respir Cell Mol Biol* 2010, **43**:109-120.
123. Toeda K, Nakamura K, Hirohata S, Hatipoglu OF, Demircan K, Yamawaki H, *et al*: Versican is induced in infiltrating monocytes in myocardial infarction. *Mol Cell Biochem* 2005, **280**:47-56.
124. Zhao H, Xiao S, Kong X, Wang J, Cao X, Gencheng W, *et al*: Neuron-glia cell communication in the traumatic stress-induced immunomodulation. *Synapse* 2011, **65**:433-440.
125. Verheyen GR, Nuijten JM, Van Hummelen P, Schoeters GR: Microarray analysis of the effect of diesel exhaust particles on in vitro cultured macrophages. *Toxicol In Vitro* 2004, **18**:377-391.
126. Thangasamy T, Subathra M, Sittadjody S, Jeyakumar P, Joyee AG, Mendoza E, *et al*: Role of L-carnitine in the modulation of immune response in aged rats. *Clin Chim Acta* 2008, **389**:19-24.
127. Yao D, Kuwajima M, Chen Y, Shiota M, Okumura Y, Yamada H, *et al*: Impaired long-chain fatty acid metabolism in mitochondria causes brain vascular invasion by a non-neurotropic epidemic influenza A virus in the newborn/suckling period: implications for influenza-associated encephalopathy. *Mol Cell Biochem* 2007, **299**:85-92.

128. Mak CM, Lam CW, Fong NC, Siu WK, Lee HC, Siu TS, *et al*: Fatal viral infection-associated encephalopathy in two Chinese boys: a genetically determined risk factor of thermolabile carnitine palmitoyltransferase II variants. *J Hum Genet* 2011.
129. Matsumoto H, Hatanaka D, Ogura Y, Chida A, Nakamura Y, Nonoyama S: Severe Human Herpesvirus 6-associated Encephalopathy in Three Children: Analysis of Cytokine Profiles and the Carnitine Palmitoyltransferase 2 Gene. *Pediatr Infect Dis J* 2011.
130. Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, *et al*: Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. *Fundam Clin Pharmacol* 2010.
131. Hai T, Wolford CC, Chang YS: ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? *Gene Expr* 2010, **15**:1-11.
132. Gilchrist M, Henderson WR, Jr., Morotti A, Johnson CD, Nachman A, Schmitz F, *et al*: A key role for ATF3 in regulating mast cell survival and mediator release. *Blood* 2010, **115**:4734-4741.
133. Litvak V, Ramsey SA, Rust AG, Zak DE, Kennedy KA, Lampano AE, *et al*: Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. *Nat Immunol* 2009, **10**:437-443.
134. Hwang HY, Kim JY, Lim JY, Chung SK, Nam JH, Park SI: Coxsackievirus B3 modulates cell death by downregulating activating transcription factor 3 in HeLa cells. *Virus Res* 2007, **130**:10-17.
135. Rosenberger CM, Clark AE, Treuting PM, Johnson CD, Aderem A: ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells. *Proc Natl Acad Sci U S A* 2008, **105**:2544-2549.

136. Granberg F, Svensson C, Pettersson U, Zhao H: Adenovirus-induced alterations in host cell gene expression prior to the onset of viral gene expression. *Virology* 2006, **353**:1-5.
137. Zhao H, Granberg F, Elfineh L, Pettersson U, Svensson C: Strategic attack on host cell gene expression during adenovirus infection. *J Virol* 2003, **77**:11006-11015.
138. Guerra S, Lopez-Fernandez LA, Garcia MA, Zaballos A, Esteban M: Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. *J Biol Chem* 2006, **281**:18734-18745.
139. Lu D, Chen J, Hai T: The regulation of ATF3 gene expression by mitogen-activated protein kinases. *Biochem J* 2007, **401**:559-567.
140. Filen S, Ylikoski E, Tripathi S, West A, Bjorkman M, Nystrom J, *et al*: Activating transcription factor 3 is a positive regulator of human IFNG gene expression. *J Immunol* 2010, **184**:4990-4999.
141. Whitmore MM, Iparraguirre A, Kubelka L, Weninger W, Hai T, Williams BR: Negative regulation of TLR-signaling pathways by activating transcription factor-3. *J Immunol* 2007, **179**:3622-3630.
142. Nguyen TT, Johnsen IB, Knetter CF, Drablos F, Fitzgerald KA, Lien E, *et al*: Differential gene expression downstream of Toll-like receptors (TLRs): role of c-Src and activating transcription factor 3 (ATF3). *J Biol Chem* 2010, **285**:17011-17019.
143. Yin X, Wolford CC, Chang YS, McConoughey SJ, Ramsey SA, Aderem A, *et al*: ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. *J Cell Sci* 2010, **123**:3558-3565.
144. Kim JY, Song EH, Lee S, Lim JH, Choi JS, Koh IU, *et al*: The induction of STAT1 gene by activating transcription factor 3 contributes to pancreatic beta-cell apoptosis and its dysfunction in streptozotocin-treated mice. *Cell Signal* 2010, **22**:1669-1680.

145. Zmuda EJ, Viapiano M, Grey ST, Hadley G, Garcia-Ocana A, Hai T: Deficiency of Atf3, an adaptive-response gene, protects islets and ameliorates inflammation in a syngeneic mouse transplantation model. *Diabetologia* 2010, **53**:1438-1450.
146. Takii R, Inouye S, Fujimoto M, Nakamura T, Shinkawa T, Prakasam R, *et al*: Heat shock transcription factor 1 inhibits expression of IL-6 through activating transcription factor 3. *J Immunol* 2010, **184**:1041-1048.
147. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Roach JC, *et al*: Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. *Nature* 2006, **441**:173-178.
148. Suganami T, Yuan X, Shimoda Y, Uchio-Yamada K, Nakagawa N, Shirakawa I, *et al*: Activating transcription factor 3 constitutes a negative feedback mechanism that attenuates saturated Fatty acid/toll-like receptor 4 signaling and macrophage activation in obese adipose tissue. *Circ Res* 2009, **105**:25-32.
149. Ho HH, Antoniv TT, Ji JD, Ivashkiv LB: Lipopolysaccharide-induced expression of matrix metalloproteinases in human monocytes is suppressed by IFN-gamma via superinduction of ATF-3 and suppression of AP-1. *J Immunol* 2008, **181**:5089-5097.
150. Gilchrist M, Henderson WR, Jr., Clark AE, Simmons RM, Ye X, Smith KD, *et al*: Activating transcription factor 3 is a negative regulator of allergic pulmonary inflammation. *J Exp Med* 2008, **205**:2349-2357.
151. Astring AG, Caren H, Andersson M, Lonroth C, Lagerstedt K, Lundholm K: COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status. *BMC Cancer* 2011, **11**:238.
152. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, *et al*: T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. *Immunity* 2008, **28**:29-39.

153. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, *et al*: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. *Nature* 2011, **472**:491-494.
154. Okamoto K, Iwai Y, Oh-Hora M, Yamamoto M, Morio T, Aoki K, *et al*: IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. *Nature* 2010, **464**:1381-1385.
155. Dzhagalov I, Giguere V, He YW: Lymphocyte development and function in the absence of retinoic acid-related orphan receptor alpha. *J Immunol* 2004, **173**:2952-2959.
156. Ding XR, Yang J, Sun DC, Lou SK, Wang SQ: Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs. *Pharmacogenomics J* 2008, **8**:61-70.
157. Keino H, Watanabe T, Sato Y, Okada AA: Anti-inflammatory effect of retinoic acid on experimental autoimmune uveoretinitis. *Br J Ophthalmol* 2010, **94**:802-807.
158. Keino H, Watanabe T, Sato Y, Okada AA: Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis. *Invest Ophthalmol Vis Sci* 2011, **52**:1548-1556.
159. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, *et al*: Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation* 2011, **123**:731-738.
160. Haimovich B, Calvano J, Haimovich AD, Calvano SE, Coyle SM, Lowry SF: In vivo endotoxin synchronizes and suppresses clock gene expression in human peripheral blood leukocytes. *Crit Care Med* 2010, **38**:751-758.
161. Journiac N, Jolly S, Jarvis C, Gautheron V, Rogard M, Trembleau A, *et al*: The nuclear receptor ROR(alpha) exerts a bi-directional regulation of IL-6 in resting and reactive astrocytes. *Proc Natl Acad Sci U S A* 2009, **106**:21365-21370.

162. Chauvet C, Bois-Joyeux B, Fontaine C, Gervois P, Bernard MA, Staels B, *et al*: The gene encoding fibrinogen-beta is a target for retinoic acid receptor-related orphan receptor alpha. *Mol Endocrinol* 2005, **19**:2517-2526.
163. Migita H, Satozawa N, Lin JH, Morser J, Kawai K: RORalpha1 and RORalpha4 suppress TNF-alpha-induced VCAM-1 and ICAM-1 expression in human endothelial cells. *FEBS Lett* 2004, **557**:269-274.
164. Berger M, Krebs P, Crozat K, Li X, Croker BA, Siggs OM, *et al*: An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence. *Nat Immunol* 2010, **11**:335-343.
165. Schwarz DA, Katayama CD, Hedrick SM: Schlafen, a new family of growth regulatory genes that affect thymocyte development. *Immunity* 1998, **9**:657-668.
166. Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, *et al*: Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. *Am J Hum Genet* 2010, **86**:88-92.
167. Hoy B, Lower M, Weydig C, Carra G, Tegtmeyer N, Geppert T, *et al*: Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion. *EMBO Rep* 2010, **11**:798-804.
168. Barbuddhe SB, Chakraborty T: Listeria as an enteroinvasive gastrointestinal pathogen. *Curr Top Microbiol Immunol* 2009, **337**:173-195.
169. Popova T, Espina V, Bailey C, Liotta L, Petricoin E, Popov S: Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells. *FEMS Immunol Med Microbiol* 2009, **56**:129-142.
170. Sugawara Y, Fujinaga Y: The botulinum toxin complex meets E-cadherin on the way to its destination. *Cell Adh Migr* 2011, **5**:34-36.
171. Yeo NK, Jang YJ: Rhinovirus infection-induced alteration of tight junction and adherens junction components in human nasal epithelial cells. *Laryngoscope* 2010, **120**:346-352.

172. Sears CL: Enterotoxigenic *Bacteroides fragilis*: a rogue among symbiotes. *Clin Microbiol Rev* 2009, **22**:349-369, Table of Contents.
173. Babbin BA, Sasaki M, Gerner-Schmidt KW, Nusrat A, Klapproth JM: The bacterial virulence factor lymphostatin compromises intestinal epithelial barrier function by modulating rho GTPases. *Am J Pathol* 2009, **174**:1347-1357.
174. Chun J, Prince A: TLR2-induced calpain cleavage of epithelial junctional proteins facilitates leukocyte transmigration. *Cell Host Microbe* 2009, **5**:47-58.
175. Sheridan BS, Lefrancois L: Regional and mucosal memory T cells. *Nat Immunol* 2011, **12**:485-491.
176. Valente ST, Gilmartin GM, Venkatarama K, Arriagada G, Goff SP: HIV-1 mRNA 3' end processing is distinctively regulated by eIF3f, CDK11, and splice factor 9G8. *Mol Cell* 2009, **36**:279-289.
177. Valente ST, Gilmartin GM, Mott C, Falkard B, Goff SP: Inhibition of HIV-1 replication by eIF3f. *Proc Natl Acad Sci U S A* 2009, **106**:4071-4078.
178. Kieft JS, Zhou K, Grech A, Jubin R, Doudna JA: Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. *Nat Struct Biol* 2002, **9**:370-374.
179. Theurl I, Zoller H, Obrist P, Datz C, Bachmann F, Elliott RM, *et al*: Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. *J Infect Dis* 2004, **190**:819-825.
180. Sizova DV, Kolupaeva VG, Pestova TV, Shatsky IN, Hellen CU: Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs. *J Virol* 1998, **72**:4775-4782.
181. Buratti E, Gerotto M, Pontisso P, Alberti A, Tisminetzky SG, Baralle FE: In vivo translational efficiency of different hepatitis C virus 5'-UTRs. *FEBS Lett* 1997, **411**:275-280.

182. Wyckoff EE, Lloyd RE, Ehrenfeld E: Relationship of eukaryotic initiation factor 3 to poliovirus-induced p220 cleavage activity. *J Virol* 1992, **66**:2943-2951.
183. Wyckoff EE, Hershey JW, Ehrenfeld E: Eukaryotic initiation factor 3 is required for poliovirus 2A protease-induced cleavage of the p220 component of eukaryotic initiation factor 4F. *Proc Natl Acad Sci U S A* 1990, **87**:9529-9533.
184. Moretti J, Chastagner P, Gastaldello S, Heuss SF, Dirac AM, Bernards R, *et al*: The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. *PLoS Biol* 2010, **8**:e1000545.
185. Fiorini E, Merck E, Wilson A, Ferrero I, Jiang W, Koch U, *et al*: Dynamic regulation of notch 1 and notch 2 surface expression during T cell development and activation revealed by novel monoclonal antibodies. *J Immunol* 2009, **183**:7212-7222.
186. Jenkinson EJ, Jenkinson WE, Rossi SW, Anderson G: The thymus and T-cell commitment: the right niche for Notch? *Nat Rev Immunol* 2006, **6**:551-555.
187. Dallman MJ, Smith E, Benson RA, Lamb JR: Notch: control of lymphocyte differentiation in the periphery. *Curr Opin Immunol* 2005, **17**:259-266.
188. Svensson A, Jakara E, Shestakov A, Eriksson K: Inhibition of gamma-secretase cleavage in the notch signaling pathway blocks HSV-2-induced type I and type II interferon production. *Viral Immunol* 2010, **23**:647-651.
189. Lu J, Verma SC, Cai Q, Robertson ES: The Single RBP-J{ κ } Site within the LANA Promoter Is Crucial for Establishing Kaposi's Sarcoma-Associated Herpesvirus Latency during Primary Infection. *J Virol* 2011, **85**:6148-6161.
190. Workman A, Sinani D, Pittayakhajonwut D, Jones C: A protein (ORF2) encoded by the latency-related gene of bovine herpesvirus 1 interacts with Notch1 and Notch3. *J Virol* 2011, **85**:2536-2546.

191. Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M, Lukacs NW, *et al*: TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. *J Clin Invest* 2009, **119**:33-46.
192. Wiethe C, Debus A, Mohrs M, Steinkasserer A, Lutz M, Gessner A: Dendritic cell differentiation state and their interaction with NKT cells determine Th1/Th2 differentiation in the murine model of *Leishmania major* infection. *J Immunol* 2008, **180**:4371-4381.
193. Schaller MA, Neupane R, Rudd BD, Kunkel SL, Kallal LE, Lincoln P, *et al*: Notch ligand Delta-like 4 regulates disease pathogenesis during respiratory viral infections by modulating Th2 cytokines. *J Exp Med* 2007, **204**:2925-2934.
194. Hayward SD, Liu J, Fujimuro M: Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. *Sci STKE* 2006, **2006**:re4.
195. Maekawa Y, Minato Y, Ishifune C, Kurihara T, Kitamura A, Kojima H, *et al*: Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. *Nat Immunol* 2008, **9**:1140-1147.
196. Chen J, Liu XS: Development and function of IL-10 IFN-gamma-secreting CD4(+) T cells. *J Leukoc Biol* 2009, **86**:1305-1310.
197. Pei J, Tang Z, Zang G, Yu Y: Blockage of Notch1 signaling modulates the T-helper (Th)1/Th2 cell balance in chronic hepatitis B patients. *Hepatol Res* 2010, **40**:799-805.
198. Wei Z, Chigurupati S, Arumugam TV, Jo DG, Li H, Chan SL: Notch Activation Enhances the Microglia-Mediated Inflammatory Response Associated With Focal Cerebral Ischemia. *Stroke* 2011.
199. Huang R, Zhou Q, Veeraragoo P, Yu H, Xiao Z: Notch2/Hes-1 pathway plays an important role in renal ischemia and reperfusion injury-associated inflammation and apoptosis and the gamma-secretase inhibitor DAPT has a nephroprotective effect. *Ren Fail* 2011, **33**:207-216.

200. Piggott K, Deng J, Warrington K, Younge B, Kubo JT, Desai M, *et al*: Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. *Circulation* 2011, **123**:309-318.
201. Briggs FB, Ramsay PP, Madden E, Norris JM, Holers VM, Mikuls TR, *et al*: Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis. *Genes Immun* 2010, **11**:199-208.
202. Song JW, Song KJ, Baek LJ, Frost B, Poncz M, Park K: In vivo characterization of the integrin beta3 as a receptor for Hantaan virus cellular entry. *Exp Mol Med* 2005, **37**:121-127.
203. Feire AL, Roy RM, Manley K, Compton T: The glycoprotein B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry. *J Virol* 2010, **84**:10026-10037.
204. Leo JC, Skurnik M: Adhesins of human pathogens from the genus yersinia. *Adv Exp Med Biol* 2011, **715**:1-15.
205. Coconnier MH, Bernet-Camard MF, Servin AL: How intestinal epithelial cell differentiation inhibits the cell-entry of Yersinia pseudotuberculosis in colon carcinoma Caco-2 cell line in culture. *Differentiation* 1994, **58**:87-94.
206. Siemens N, Patenge N, Otto J, Fiedler T, Kreikemeyer B: Streptococcus pyogenes M49 Plasminogen/Plasmin Binding Facilitates Keratinocyte Invasion via Integrin-Integrin-linked Kinase (ILK) Pathways and Protects from Macrophage Killing. *J Biol Chem* 2011, **286**:21612-21622.
207. Wu J, Weening EH, Faske JB, Hook M, Skare JT: Invasion of eukaryotic cells by Borrelia burgdorferi requires beta(1) integrins and Src kinase activity. *Infect Immun* 2011, **79**:1338-1348.
208. Kadioglu A, De Filippo K, Bangert M, Fernandes VE, Richards L, Jones K, *et al*: The integrins Mac-1 and alpha4beta1 perform crucial roles in neutrophil and T cell

- recruitment to lungs during *Streptococcus pneumoniae* infection. *J Immunol* 2011, **186**:5907-5915.
- 209.** Kapetanovic R, Parlato M, Fitting C, Quesniaux V, Cavaillon JM, Adib-Conquy M: Mechanisms of TNF induction by heat-killed *Staphylococcus aureus* differ upon the origin of mononuclear phagocytes. *Am J Physiol Cell Physiol* 2011, **300**:C850-859.
- 210.** Racine R, Chatterjee M, Winslow GM: CD11c expression identifies a population of extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody responses during intracellular bacterial infection. *J Immunol* 2008, **181**:1375-1385.
- 211.** Bentz GL, Yurochko AD: Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. *Proc Natl Acad Sci U S A* 2008, **105**:5531-5536.
- 212.** Gu L, Wang H, Guo YL, Zen K: Heparin blocks the adhesion of *E. coli* O157:H7 to human colonic epithelial cells. *Biochem Biophys Res Commun* 2008, **369**:1061-1064.
- 213.** Yoshida S, Sudo T, Niimi M, Tao L, Sun B, Kambayashi J, *et al*: Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito. *Blood* 2008, **111**:2007-2014.
- 214.** DeNucci CC, Shimizu Y: beta1 integrin is critical for the maintenance of antigen-specific CD4 T cells in the bone marrow but not long-term immunological memory. *J Immunol* 2011, **186**:4019-4026.
- 215.** Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, *et al*: LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. *Cancer Res* 2011, **71**:1989-1998.
- 216.** Franke A, Hampe J, Rosenstiel P, Becker C, Wagner F, Hasler R, *et al*: Systematic association mapping identifies NELL1 as a novel IBD disease gene. *PLoS One* 2007, **2**:e691.

- 217.** Marabese I, de Novellis V, Palazzo E, Scafuro MA, Vita D, Rossi F, *et al*: Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice. *Neuropharmacology* 2007, **52**:253-262.
- 218.** Collard CD, Park KA, Montalto MC, Alapati S, Buras JA, Stahl GL, *et al*: Neutrophil-derived glutamate regulates vascular endothelial barrier function. *J Biol Chem* 2002, **277**:14801-14811.
- 219.** Boldyrev AA, Johnson P: Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. *J Alzheimers Dis* 2007, **11**:219-228.
- 220.** Taylor DL, Pirianov G, Holland S, McGinnity CJ, Norman AL, Reali C, *et al*: Attenuation of proliferation in oligodendrocyte precursor cells by activated microglia. *J Neurosci Res* 2010, **88**:1632-1644.